Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of oral MK-0974 for acute treatment of migraine
2006-006187-35Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of telcagepant in migraine (3 arms), sponsored by Merck & Co. Primary endpoints: Headache freedom at 2 hours, Freedom from photophobia at 2 hours and 3 more. Started Feb 2007; status: completed.
02
Drugs
telcagepant
03
Conditions
migraine
Beyond the preview
Go deeper on 2006-006187-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006187-35.